Completed
How Can Biomarkers (D-dimer, fibrinogen) Help Make Anticoagulation Decisions?
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Epidemiology and Treatment of MIS-C
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 HOW does MIS-C differ from Kawasaki disease, KD, shock, and TSS
- 3 Can MIS-C be distinguished from other infectious and inflammatory diseases ?
- 4 Clinical features conclusions
- 5 What is the relationship of MISC to COVID 19 and SARS Cov2?
- 6 Possible mechanism for acquired immunity mediating inflammation and organ damage ??
- 7 When Should Immunomodulatory Treatments Be Started for MIS-C?
- 8 Do All MIS-C Patients Need Treatment?
- 9 Treatment For MIS-C Derived From Kawasaki Disease Management
- 10 Which Patients Need Anticoagulation?
- 11 Should Therapy Change If Enlarging Coronary Aneurysm?
- 12 How Should Management Change in Resource-limited Environments?
- 13 Does Sequence of Treatment Matter?
- 14 How Can Biomarkers (D-dimer, fibrinogen) Help Make Anticoagulation Decisions?
